+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

H

Actively Recruiting

The trial focuses on hypertension treatment in Nigeria by expanding the successful implementation of the WHO HEARTS package from the Federal Capital Territory to five new states across different geopolitical zones. It aims to improve and sustain hypertension control in primary healthcare centers across these regions. This health services research evaluates the impact of this program over several years. The intervention involves implementing a modified WHO HEARTS Hypertension Treatment Bundle in 50 primary healthcare centers across five Nigerian states. After a 12-month pre-implementation period, these centers will enter a 24-month phase including health worker training, non-physician hypertension screening and treatment, simplified guidelines, monthly audits, supply chain strengthening, and a drug revolving fund to enhance medication accessibility. Participants will be adults aged 18 years or older with elevated blood pressure or a history of hypertension, including pregnant and cognitively impaired adults. The study measures effectiveness and implementation outcomes over 36 months, including blood pressure control, medication availability, training participation, and treatment adherence. The program excludes minors and detained individuals. Participant involvement includes hypertension screening, treatment initiation, monitoring, and data collection across the participating primary healthcare centers.

Age: 18Years +All GendersPhase Not Applicable
49 locations
A

Actively Recruiting

Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.

Age: 18Years +All GendersPhase 3
52 locations